Ignite Creation Date:
2024-05-06 @ 12:23 AM
Last Modification Date:
2024-10-26 @ 10:49 AM
Study NCT ID:
NCT01568190
Status:
COMPLETED
Last Update Posted:
2015-01-06
First Post:
2012-03-29
Brief Title:
An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
An Open Trial to Asses the Tolerability of AVANZ Mite Mix Immunotherapy
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AV-M-01
Brief Summary:
The purpose of the trial is to assess the tolerability of the up-dosing phase of AVANZ Mite mix
Detailed Description:
The frequency of patients with adverse reactions will be the primary endpoint
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-002017-11 | EUDRACT_NUMBER | None | None |